BridgeBio (BBIO) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 Jun, 2026Opening remarks and agenda
Meeting commenced as an interactive webcast, following corporate bylaws and Delaware law.
Stockholders and guests were welcomed, and the agenda included reviewing and voting on proposals outlined in the proxy statement.
Voting procedures and rules of conduct were explained, with polls open during the meeting.
Board and executive committee updates
Directors and officers present were introduced, including the CEO, CFO, and other key executives.
Representatives from Deloitte (auditors), Goodwin Procter (outside counsel), and American Election Services (inspector of elections) attended.
Shareholder proposals
Five proposals were presented: election of three directors, advisory vote on executive compensation, advisory vote on frequency of compensation votes, ratification of Deloitte as auditor, and amendment to the stock option plan.
Board recommended approval of all proposals.
Latest events from BridgeBio
- Q2 2026 revenue surged on strong product sales and $1B in new preferred equity financing.BBIO
Q2 2026 - Multiple first-in-class rare disease therapies advance toward US launches, backed by $1.7B cash.BBIO
Corporate presentation - ATTR-CM launch outperformed, with three late-stage pipeline catalysts expected within 18 months.BBIO
Bank of America 2025 Healthcare Conference - Accelerating sales and robust clinical data drive growth and pipeline momentum in rare diseases.BBIO
UBS Global Healthcare Conference 2025 - Oral infigratinib significantly improved growth and body proportions in children with achondroplasia.BBIO
Conference presentation - Oral infigratinib delivers record growth and proportionality benefits with strong safety in achondroplasia.BBIO
Study result - Q3 revenue surged on new launches; pipeline and cash position support 2026 NDA filings.BBIO
Q3 2025 - Infigratinib delivers sustained growth and proportionality gains in achondroplasia with strong safety.BBIO
Study Result - Attruby launch drove $36.7M in new revenue, $116.6M total, and rapid adoption, but net loss widened.BBIO
Q1 2025